Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies
暂无分享,去创建一个
[1] N. Damle,et al. Biopharmaceutical drug discovery using novel protein scaffolds. , 2006, Current opinion in biotechnology.
[2] Arne Skerra,et al. Construction of an Artificial Receptor Protein (“Anticalin”) Based on the Human Apolipoprotein D , 2004, Chembiochem : a European journal of chemical biology.
[3] P. Parren,et al. Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.
[4] W. Dijk,et al. α1-Acid Glycoprotein , 1995 .
[5] A. Wu,et al. Tailoring antibodies for radionuclide delivery , 2006, Expert opinion on drug delivery.
[6] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[7] R. Huber,et al. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Paesen,et al. Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata , 2005, The Journal of Immunology.
[9] Edward W. Voss,et al. Fluorescein hapten : an immunological probe , 1984 .
[10] Gary Walsh,et al. Biopharmaceutical benchmarks 2006 , 2006, Nature Biotechnology.
[11] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] Min Zhang,et al. Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.
[13] J. Andersen,et al. Inhibition of Hemostasis by a High Affinity Biogenic Amine-binding Protein from the Saliva of a Blood-feeding Insect* , 2003, The Journal of Biological Chemistry.
[14] J. Bausch,et al. Monoclonal antibodies. , 1990, Bioprocess technology.
[15] I. Korndörfer,et al. Crystallographic analysis of an “anticalin” with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region , 2003, Proteins.
[16] B. Comin-Anduix,et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Gary Walsh,et al. Biopharmaceutical benchmarks , 2000, Nature Biotechnology.
[18] L. Steinman. Immune Therapy for Autoimmune Diseases , 2004, Science.
[19] A. Pavlou,et al. Monoclonal antibodies market , 2004, Nature Reviews Drug Discovery.
[20] Arne Skerra,et al. Solubility engineering and crystallization of human apolipoprotein D , 2006, Protein science : a publication of the Protein Society.
[21] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[22] Rational engineering of a fluorescein-binding anticalin for improved ligand affinity , 2005, Biological chemistry.
[23] A. Skerra. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. , 2001, Journal of biotechnology.
[24] Hubertus Haas,et al. Human Tear Lipocalin Exhibits Antimicrobial Activity by Scavenging Microbial Siderophores , 2004, Antimicrobial Agents and Chemotherapy.
[25] B. Nardelli,et al. Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys , 2002, Journal of Pharmacology and Experimental Therapeutics.
[26] L. Polito,et al. Expression of CTLA‐4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin‐mediated apoptosis: results of in vitro studies , 2004, Clinical and experimental immunology.
[27] A. Skerra. Lipocalins as a scaffold. , 2000, Biochimica et biophysica acta.
[28] J. Andersen,et al. Purification, Cloning, Expression, and Mechanism of Action of a Novel Platelet Aggregation Inhibitor from the Salivary Gland of the Blood-sucking Bug, Rhodnius prolixus * , 2000, The Journal of Biological Chemistry.
[29] T. Fournier,et al. Alpha-1-acid glycoprotein. , 2000, Biochimica et biophysica acta.
[30] A. Skerra,et al. Duocalins: Engineered Ligand-Binding Proteins with Dual Specificity Derived from the Lipocalin Fold , 2001, Biological chemistry.
[31] A. Skerra,et al. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. , 2000, Journal of molecular biology.
[32] B. Ryffel,et al. Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma , 2004, The Journal of Immunology.
[33] W. Schleuning,et al. An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis. , 1994, The Journal of biological chemistry.
[34] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[35] T. Caspari,et al. REVERSAL OF DIGOXIN CARDIAC TOXICITY BY AN ANTICALIN (DIGICAL II) IN THE ANAESTHETIZED GUINEA PIG , 2004 .
[36] A. Skerra,et al. The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. , 1994, European journal of biochemistry.
[37] P. Nygren,et al. Binding proteins from alternative scaffolds. , 2004, Journal of immunological methods.
[38] K. Mori,et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia , 2006, Current opinion in nephrology and hypertension.
[39] R. Strong,et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. , 2002, Molecular cell.
[40] Ian R. Drexler,et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. , 2005, The Journal of clinical investigation.
[41] K. Ohlsson,et al. Studies of the release and turnover of a human neutrophil lipocalin. , 1995, Scandinavian journal of clinical and laboratory investigation.
[42] Huub Schellekens,et al. Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.
[43] H. Erdjument-Bromage,et al. An iron delivery pathway mediated by a lipocalin. , 2002, Molecular cell.
[44] S. Moestrup,et al. The endocytic receptor megalin binds the iron transporting neutrophil‐gelatinase‐associated lipocalin with high affinity and mediates its cellular uptake , 2005, FEBS letters.
[45] I. Korndörfer,et al. The 1.8-Å Crystal Structure of Human Tear Lipocalin Reveals an Extended Branched Cavity with Capacity for Multiple Ligands* , 2005, Journal of Biological Chemistry.
[46] P. Carter,et al. Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.
[47] A. Korman,et al. Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques , 2003, The Journal of Immunology.
[48] P. Ping,et al. A Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A , 2007, Science.
[49] E. Haber,et al. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. , 1984, The Journal of pharmacology and experimental therapeutics.
[50] C. V. Jongeneel,et al. Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. , 2005, Cancer immunity.
[51] I. Korndörfer,et al. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. , 2003, Journal of molecular biology.
[52] Morten Nielsen,et al. The validity of predicted T-cell epitopes. , 2006, Trends in biotechnology.
[53] D I Stuart,et al. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. , 1999, Molecular cell.
[54] A. Skerra,et al. Comparative ligand-binding analysis of ten human lipocalins. , 2006, Biochimica et biophysica acta.
[55] David Schrama,et al. Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.
[56] L. Lögdberg,et al. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. , 2000, Biochimica et biophysica acta.
[57] I. Pastan. Immunotoxins containing Pseudomonas exotoxin A: a short history , 2003, Cancer Immunology, Immunotherapy.
[58] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[59] A. Skerra,et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Andersen,et al. Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. , 2000, Biochimica et biophysica acta.
[61] J. Blattman,et al. Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.
[62] R. Werner,et al. Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.
[63] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[64] Colin Ratledge,et al. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. , 2005, Structure.
[65] A. Skerra. Imitating the humoral immune response. , 2003, Current opinion in chemical biology.
[66] T. Connolly,et al. Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodoros moubata. , 1993, The Journal of biological chemistry.
[67] B. Redl,et al. Molecular Cloning of a Novel Lipocalin-1 Interacting Human Cell Membrane Receptor Using Phage Display* , 2001, The Journal of Biological Chemistry.
[68] Arne Skerra,et al. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". , 2005, Drug discovery today.
[69] Shizuo Akira,et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron , 2004, Nature.
[70] D R Flower,et al. The lipocalin protein family: structure and function. , 1996, The Biochemical journal.